Cereno Scientific: FDA approves IND application
Redeye is encouraged by FDA approving Cereno’s IND application to start its phase II trial in pulmonary arterial hypertension with lead candidate CS1. We briefly comment on the news and Cereno's ongoing TO1 warrant exercise.
CB
Christian Binder
Disclosures and disclaimers